Personalis Patents

Patent portfolio assigned to Personalis (verified via public assignee records). US advanced-genomics company (NASDAQ: PSNL; NeXT / NeXT Personal MRD platforms). Competitors from FinancialContent. Customers/partners (Moderna, Natera, Merck strategic investor, Tempus, Myriad) confirmed via Personalis investor releases and Natera's site. has_patents=true: multiple issued US patents (e.g. 11,299,783; 11,384,394) and active MRD patent-infringement litigation vs Foresight Diagnostics; exact count not enumerated.